Trial Profile
A Phase I Trial of Fostamatinib and Chronic Graft vs. Host Disease Development After Allogeneic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Mar 2023
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 15 Mar 2023 Status changed from active, no longer recruiting to completed.
- 09 Jan 2023 According to a Rigel Pharmaceuticals media release, data from the trial were published in the journal Transplantation and Cellular Therapy.
- 14 Jul 2022 Planned End Date changed from 1 Jan 2024 to 1 Dec 2022.